TrialAnnals of medicine2026

Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.

Liyu Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.